Actively Recruiting
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
Led by University Hospital, Basel, Switzerland · Updated on 2026-03-02
152
Participants Needed
3
Research Sites
119 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine would significantly improve the success rate of TACE treatment.
CONDITIONS
Official Title
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Age 18 years or older
- Diagnosis of hepatocellular carcinoma by biopsy or imaging (CT or MRI)
- At least one target tumor lesion untreated
- Target tumor size between 3 cm and 8 cm in diameter
- Preserved liver function without jaundice, ascites, or overt hepatic encephalopathy
- Women of childbearing potential must agree to abstain from heterosexual intercourse or use contraception for at least 3 months after treatment
You will not qualify if you...
- Prior systemic therapy for advanced hepatocellular carcinoma
- Diffuse tumor lesions, spread outside liver, or blood vessel invasion
- Hepatic encephalopathy
- Uncontrolled fluid buildup in abdomen or chest
- Jaundice
- Severe low blood pressure, shock, or need for vasoactive drugs
- Decompensated heart failure classified as NYHA class IV
- Severe kidney impairment with eGFR less than 15 mL/min/1.73 m2
- Heart attack within past 6 months
- Life expectancy less than 12 weeks
- Allergy or sensitivity to calcium channel blockers
- Unable to follow study procedures due to language, psychological, or cognitive issues
- Pregnancy, breastfeeding, or planning pregnancy during treatment or within 3 months after
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
2
Hôpitaux Universitaires de Genève
Geneva, Switzerland, 1205
Actively Recruiting
3
Kantonsspital St. Gallen
Sankt Gallen, Switzerland, 9007
Actively Recruiting
Research Team
F
Fahim Ebrahimi, PD Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here